Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

$CHRS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $CHRS alert in real time by email

REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024.

Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting functions at multi-billion-dollar global companies. Her experience includes more than 17 years at Merck, where she held positions of increasing financial management responsibility. As Global Controller at Merck, Ms. Karachun managed a global team responsible for all accounting and operational aspects of the company.

"We are delighted to welcome Rita to our Board, and are confident that her impressive experience in finance, accounting, and operational transformation will be invaluable to Coherus," said Denny Lanfear, Coherus Chairman and Chief Executive Officer. "Rita's deep understanding of the promise of I-O therapies, combined with her world-class financial expertise, will serve as a vital resource as we transform our Company and advance our pipeline."

"I believe Coherus has both a solid, forward-looking vision of the innovative oncology space as well as a highly talented management team capable of successfully executing their strategic plans," said Ms. Karachun. "I joined Merck at the outset of its effort to bring innovative oncology therapies to patients, and I am thrilled to now join the Coherus Board of Directors as the Company embarks on its own journey to develop the next generation of I-O therapies aimed at extending the survival of patients with cancer."

While at Merck, Ms. Karachun served as a member of the Finance Risk Committee, responsible for global oversight of capital structure, dividend policy, insurance coverage, and more; the Enterprise Risk Management Committee, responsible for global oversight of risks, developing remediation plans, and ensuring a robust board governance process; and the Benefits Executive Oversight Committee, responsible for evaluation of health care and pension benefit plans, as well as global restructuring activities.

Prior to joining Merck, Ms. Karachun spent 16 years at AT&T, including serving as Assistant Controller – Chief Accountant at AT&T and as Finance Director at AT&T Capital Corp. She began her career as an auditor with Arthur Andersen LLP.

Ms. Karachun currently serves on the board of Jersey Battered Women's Services, a not-for-profit organization. She is also on advisory committees for Financial Executives International and the American Institute of Certified Public Accountants.

Ms. Karachun is a graduate of Fairleigh Dickinson University. She completed her Certified Public Accountant (CPA) certification in New Jersey. She also holds a Chartered Global Management Accountant (CGMA) certification.

As a matter of practice, the Coherus Board of Directors regularly evaluates the composition of the Board and considers how they can maintain the appropriate mix of skills, qualifications and diversity of backgrounds to best oversee the business and long-term strategy of the company.

About Coherus BioSciences

Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline that is expected to be synergistic with its proven commercial capabilities in oncology.

Coherus' immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in two ongoing clinical studies: a Phase 1/2 study in advanced solid tumors and a Phase 2 study in hepatocellular carcinoma. CHS-114 is a highly selective, competitively positioned, cytolytic anti-CCR8 antibody currently in a Phase 1 study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the novel pathway ILT4.

Coherus markets LOQTORZI® (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®, and YUSIMRY® (adalimumab-aqvh), a biosimilar of Humira®.

Neulasta® is a registered trademark of Amgen, Inc.

Humira® is a registered trademark of AbbVie Inc.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Coherus' ability to identify synergies between its I-O pipeline and its commercial operations; Coherus' ability to advance its pipeline and Coherus' expectations that its I-O therapies will extend patient survival.

Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus' actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks related to Coherus' existing and potential collaboration partners; risks of Coherus' competitive position; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review and the timing of Coherus' regulatory filings; the risk of FDA review issues; the risks of competition; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus' products and product candidates; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus' business in general, see Coherus' quarterly filing on Form 10-Q for the fiscal quarter ended March 31, 2024 filed with the Securities and Exchange Commission on May 9, 2024, including the section therein captioned "Risk Factors" and in other documents Coherus files with the Securities and Exchange Commission.

UDENYCA®, UDENYCA® ONBODY™, YUSIMRY® and LOQTORZI®, whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners unless otherwise noted. Trademarks and trade names of other companies appearing in this press release are, to the knowledge of Coherus, the property of their respective owners.

Coherus BioSciences Contact Information:

For investors:

Jami Taylor, MBA, IRC

Head of Investor Relations

IR@coherus.com

For media:

Jodi Sievers

VP, Corporate Communications

media@coherus.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d8109de9-4666-457b-aca5-ef0b728dac16



Primary Logo

Get the next $CHRS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CHRS

DatePrice TargetRatingAnalyst
8/16/2024$4.00 → $1.50Buy → Neutral
UBS
11/17/2023$11.00Outperform
Robert W. Baird
11/8/2023Buy → Hold
Maxim Group
7/24/2023$12.00Buy
Citigroup
5/1/2023$24.00Buy
Truist
3/28/2023$11.00Neutral → Buy
UBS
6/14/2022$7.00Neutral
UBS
3/7/2022$15.00Overweight → Neutral
JP Morgan
More analyst ratings

$CHRS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes

    – Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company, NASDAQ:CHRS) announced today that it has entered into privately negotiated transactions (the "Repurchases") with certain holders (the "Holders") of its 1.500% Convertible Senior Subordinated Notes due 2026 (the "Convertible Notes"), pursuant to which the Company agreed to repurchase approximately $170 million aggregate principal amount of the Convertible Notes from such holders at a cash repurchase price equal to 100% of their principal amount, together with the

    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

    REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), has been selected for a poster presentation at the upcoming 2025 AACR Annual Meeting, being held April 25-30, 2025, at McCormick Place Convention Center in Chicago, Illinois. AACR 2025 Presentation Details Title: Phase 1 study of anti-CCR8 a

    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

    – Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% year-over-year –– LOQTORZI® net revenue increased 29% quarter-over-quarter – – UDENYCA divestiture on track with Special Meeting of Shareholders taking place March 11, 2025; transaction expected to close late in the first quarter or early in the second quarter of 2025 – – Post divestiture expected cash of approximately $250 million, with cash runway exceeding two years; Company headcount to be reduced by approximately 30% – – Catalyst-driven 2025/2026 with multiple clinical data readouts across the Company's innovative oncology pipeline – – Conferenc

    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CHRS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CHRS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CHRS
SEC Filings

See more

$CHRS
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:

    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:

    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CHRS
Leadership Updates

Live Leadership Updates

See more
  • Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

    REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting functions at multi-billion-dollar global companies. Her experience includes more than 17 years at Merck, where she held positions of increasing financial management responsibility. As Global Controller at Merck, Ms. Karachun managed a global team responsible for all accou

    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors

     – Recognized biopharma commercialization and market access leader to support Coherus' strategic vision and multiple product launches – REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced the appointment to its Board of Directors of biopharma commercialization and market access expert Michael Ryan, Pharm. D. Dr. Ryan has four decades of experience working in academia and the biopharmaceutical industry bringing high-value therapeutics to patients. Dr. Ryan's distinguished career includes most recently serving as Senior Vice President and Head for U.S. and Worldwide Value, Access, Pricing and Health Ec

    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Coherus BioSciences Appoints Dr. Jill O'Donnell-Tormey to its Board of Directors

    - Dr. O'Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute's efforts to advance cancer immunotherapies - REDWOOD CITY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (("Coherus", NASDAQ:CHRS) today announced the appointment of cancer immunotherapy leader Jill O'Donnell-Tormey, Ph.D., to its Board of Directors. Dr. O'Donnell-Tormey will also serve on the Nominating and Corporate Governance Committee of the Board of Directors. Dr. O'Donnell-Tormey is the Chief Executive Officer and Director of Scientific Affairs of the Cancer Research Institute ("CRI"), a nonprofit organization dedicated exclusively to

    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CHRS
Financials

Live finance-specific insights

See more
  • Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

    REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call Information When: Monday, March 10, 2025, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.me

    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.

    - Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor - - Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, clinical-stage interleukin-27 (IL-27) antagonist, and CHS-114, a highly selective chemokine receptor 8 (CCR8) antibody - - Post-closing proceeds to repay the entirety of the company's $230 million convertible notes due April 2026 - - Coherus management to host investor conference call today, Tuesday, December 3, 2024, at 8:00 a.m. Eastern Time - REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE

    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

    REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Wednesday, November 6, 2024, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through

    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CHRS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more